サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1310297

前立腺がん診断薬市場：検査タイプ別（確認検査、予備検査）、年齢層別（55-75歳、55歳未満、75歳以上）、エンドユーザー別-2023-2030年の世界予測

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 188 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
前立腺がん診断薬市場：検査タイプ別（確認検査、予備検査）、年齢層別（55-75歳、55歳未満、75歳以上）、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

前立腺がん診断薬の世界市場は大きく成長し、2023年には12億7,629万米ドル、CAGR14.18%と予測され、2030年には32億3,316万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の前立腺がん診断薬市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供しています：

  • 市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供
  • 市場の開拓度：有利な新興市場に関する詳細な情報を提供
  • 市場の多様化：新製品の発売に関する詳細情報を提供、
  • 市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響に関する包括的な理解を提供
  • 競合の評価と情報：市場シェア、戦略、製品、認証に関する徹底的な評価を提供、
  • 製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問に回答しています：

  • 世界の前立腺がん診断薬市場の市場規模および予測は？
  • 予測期間中に世界の前立腺がん診断薬市場を形成するCOVID-19の阻害要因および影響は？
  • 世界の前立腺がん診断薬市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？
  • 前立腺がん診断薬の世界市場における競争戦略は？
  • 前立腺がん診断薬の世界市場における技術動向と規制の枠組みは？
  • 前立腺がん診断薬の世界市場における主要ベンダーの市場シェアは？
  • 前立腺がん診断薬の世界市場への参入に適していると考えられる形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 高齢化人口の増加と前立腺がんの有病率の増加
      • 診断技術の進歩とがんに関する意識の向上に向けた政府の取り組みの拡大
    • 抑制要因
      • 厳しい規制と高額な診断コスト
    • 機会
      • 医薬品の革新とゲノミクスとプロテオミクスの開発
      • 前立腺がんを正確に検出するための画像調査と進歩
    • 課題
      • 臨床試験の成功率が低い
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 前立腺がん診断薬市場テストタイプ別

  • 確認検査
    • 生検
    • PCA3テスト
    • 経直腸超音波検査
  • 予備テスト

第7章 前立腺がん診断薬市場：年齢層別

  • 55～75歳
  • 年齢<55
  • 年齢>75

第8章 前立腺がん診断薬市場：エンドユーザー別

  • がん調査
  • 病院関連検査室
  • 独立した診断研究所

第9章 南北アメリカの前立腺がん診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の前立腺がん診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの前立腺がん診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2030 (%)
  • FIGURE 5. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2022 VS 2030 (%)
  • FIGURE 6. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 9. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 6. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCA3 TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TRANS-RECTAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRELIMINARY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE 55-75, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE <55, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE>75, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL ASSOCIATED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 188. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 189. PROSTATE CANCER DIAGNOSTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-A339DAEFAC1D

The Global Prostate Cancer Diagnostics Market is forecasted to grow significantly, with a projected USD 1,276.29 million in 2023 at a CAGR of 14.18% and expected to reach a staggering USD 3,233.16 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Prostate Cancer Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Prostate Cancer Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Test Type, market is studied across Confirmatory Tests and Preliminary Tests. The Confirmatory Tests is further studied across Biopsy, PCA3 Tests, and Trans-Rectal Ultrasound. The Confirmatory Tests is projected to witness significant market share during forecast period.

Based on Age Group, market is studied across Age 55-75, Age <55, and Age>75. The Age>75 is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Cancer Research Institutes, Hospital Associated Laboratories, and Independent Diagnostic Laboratories. The Cancer Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Prostate Cancer Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

  • Market Penetration: Provides comprehensive information on the market offered by the key players
  • Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  • Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
  • Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • What is the market size and forecast of the Global Prostate Cancer Diagnostics Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Prostate Cancer Diagnostics Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Prostate Cancer Diagnostics Market?
  • What is the competitive strategic window for opportunities in the Global Prostate Cancer Diagnostics Market?
  • What are the technology trends and regulatory frameworks in the Global Prostate Cancer Diagnostics Market?
  • What is the market share of the leading vendors in the Global Prostate Cancer Diagnostics Market?
  • What modes and strategic moves are considered suitable for entering the Global Prostate Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Prostate Cancer Diagnostics Market, by Test Type, 2022 vs 2030
  • 4.3. Prostate Cancer Diagnostics Market, by Age Group, 2022 vs 2030
  • 4.4. Prostate Cancer Diagnostics Market, by End-User, 2022 vs 2030
  • 4.5. Prostate Cancer Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence rate of prostate cancer
      • 5.1.1.2. Growing government's initiatives for advancement in technology in diagnosis and creating awareness regarding cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations and high cost of diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in drugs and developments in genomics and proteomics
      • 5.1.3.2. Imaging research and advancements for accurate detection of prostate cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Low success rate of clinical trials
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Prostate Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Confirmatory Tests
    • 6.2.1. Biopsy
    • 6.2.2. PCA3 Tests
    • 6.2.3. Trans-Rectal Ultrasound
  • 6.3. Preliminary Tests

7. Prostate Cancer Diagnostics Market, by Age Group

  • 7.1. Introduction
  • 7.2. Age 55-75
  • 7.3. Age <55
  • 7.4. Age>75

8. Prostate Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Hospital Associated Laboratories
  • 8.4. Independent Diagnostic Laboratories

9. Americas Prostate Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Prostate Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Prostate Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing